-
4 days ago | 
hcplive.com | Diana Isaacs |Natalie Bellini
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!Full results from the SURMOUNT-5 trial show tirzepatide (Zepbound) led to significantly greater weight loss than semaglutide 2.4 mg (Wegovy) in adults with obesity, according to findings published in The New England Journal of Medicine and presented at the 32nd European Congress on Obesity.
-
1 week ago | 
hcplive.com | Diana Isaacs |Natalie Bellini
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! 00:00:30 Dexcom G7 15-Day Sensor Approval 00:02:11 Challenges with Sensor Lifespan 00:06:00 Education and Replacement Process 00:09:27 Accuracy and FDA Approval Details 00:11:37 Libre's New Mobile App 00:16:55 Integration with Gluco 00:19:41 Medtronic's Simplera Sync Approval 00:23:03 Future Collaborations and Algorithms 00:28:05 Final Thoughts and Wrap-Up In this episode of Diabetes Dialogue: Technology,...
-
2 weeks ago | 
hcplive.com | Natalie Bellini |Diana Isaacs
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! 00:00:01 Introduction and Participant Backgrounds 00:01:18 Overview of MASH and Insulin Resistance 00:03:28 Phase 2 and Phase 3 Trials of Semaglutide 00:07:23 Significant Findings and Clinical Implications 00:09:44 Challenges and Future Directions 00:14:50 Mechanism of Action and Weight Loss 00:17:39 Data on Weight Loss and Liver Improvement 00:20:42 Potential for FDA Approval and Future Studies 00:25:04...
-
2 weeks ago | 
hcplive.com | Diana Isaacs |Natalie Bellini
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! 00:00:01 Catalyst Trial Overview and Introduction 00:01:37 Patient Criteria and Initial Findings 00:04:18 Implications and Next Steps 00:05:23 Adrenal Imaging and Cardiac Disorders 00:07:22 Clinical Implications and Future Research 00:09:13 Demographic Differences and Future Directions In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD,...
-
3 weeks ago | 
hcplive.com | Natalie Bellini |Diana Isaacs
NewsPodcastApril 24, 2025Author(s):,Fact checked by:In this episode, hosts explore promising results of orforglipron, a new oral GLP-1 receptor agonist, showing significant A1C reduction and weight loss potential.
-
4 weeks ago | 
hcplive.com | Diana Isaacs |Natalie Bellini
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this episode, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, break down a pair of studies examining the effects of semaglutide...
-
1 month ago | 
hcplive.com | Diana Isaacs |Natalie Bellini
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! 00:00:00 Introduction 00:02:18 Inspiration Behind the Paper 00:04:12 Challenges in Implementing T1D Screening 00:07:32 Educating Providers and Overcoming Barriers 00:09:32 Addressing Misdiagnosis of Diabetes 00:12:01 Inpatient Screening Practices 00:16:13 Support and Resources for Patients with Positive Antibodies 00:20:01 Conclusion and Final Thoughts In this episode of Diabetes Dialogue, hosts Diana...
-
1 month ago | 
consultantlive.com | Natalie Bellini |Diana Isaacs
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this episode, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, explored two key trial updates in type 2 diabetes (T2D) care at the...
-
1 month ago | 
hcplive.com | Natalie Bellini |Diana Isaacs
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this episode, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, explored two key trial updates in type 2 diabetes (T2D) care at the...
-
1 month ago | 
hcplive.com | Diana Isaacs |Natalie Bellini
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this episode, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, reflect on major announcements and product updates from the Advanced...
